

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product datasheet for TL313113V

HAP40 (F8A1) Human shRNA Lentiviral Particle (Locus ID 8263)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	HAP40 (F8A1) Human shRNA Lentiviral Particle (Locus ID 8263)
Locus ID:	8263
Synonyms:	DXS522E; F8A; HAP40
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	F8A1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	<u>NM 012151, NM 012151.1, NM 012151.2, NM 012151.3, BC039693, BC071963, BC071963.1</u>
UniProt ID:	<u>P23610</u>
Summary:	This gene is contained entirely within intron 22 of the factor VIII gene; spans less than 2 kb, and is transcribed in the direction opposite of factor VIII. A portion of intron 22 (int22h), containing F8A, is repeated twice extragenically closer to the Xq telomere. Although its function is unknown, the observation that this gene is conserved in the mouse implies it has some function. Unlike factor VIII, this gene is transcribed abundantly in a wide variety of cell types. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .




This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

STATISTICS CONTRACTOR CONTRACTOR STRATE STRATE STRATE STRATE STRATE STRATE STRATE STRATES STRA


Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

Product images:



GFP signal was observed under microscope at 48 hours after transduction of TL313113A virus into HEK293 cells. TL313113A virus was prepared using lenti-shRNA TL313113A and [TR30037] packaging kit.

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 

GFP signal was observed under microscope at 48 hours after transduction of TL313113B virus into HEK293 cells. TL313113B virus was prepared using lenti-shRNA TL313113B and [TR30037] packaging kit.

GFP signal was observed under microscope at 48 hours after transduction of [TL313113C] virus into HEK293 cells. [TL313113C] virus was prepared using lenti-shRNA [TL313113C] and [TR30037] packaging kit.

GFP signal was observed under microscope at 48 hours after transduction of [TL313113D] virus into HEK293 cells. [TL313113D] virus was prepared using lenti-shRNA [TL313113D] and [TR30037] packaging kit.

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US